Skyhawk Therapeutics Patent Granted for RNA Splicing Modulators
Summary
USPTO granted patent US12612397B2 to Skyhawk Therapeutics, Inc. on April 28, 2026, covering small molecule splicing modulator compounds and pharmaceutical compositions for modulating mRNA splicing to treat disease. The patent names inventors Michael Luzzio, Brian Lucas, and Daniel Brian Horne, with 14 allowed claims under CPC classifications C07D 451/06 and C07D 451/14. Filing date was July 29, 2021, under application number 17388097.
About this source
Granted patents in USPTO classification C07D, covering heterocyclic organic compounds: the chemical core of most small-molecule drugs. Around 160 grants a month. Unlike applications, grants are enforceable. This feed is the best public-domain signal of which small-molecule compositions have just become defensible IP, which matters for generic entry timing, freedom-to-operate opinions, and competitive intelligence. Watch this if you practice pharma IP law, manage a drug discovery patent portfolio, advise on compound licensing, or scout ANDA opportunities as brand drugs approach loss of exclusivity. Recent grants cover apalutamide process improvements and bioactive phenolate ionic complexes.
What changed
USPTO granted patent US12612397B2 to Skyhawk Therapeutics, Inc. on April 28, 2026. The patent covers small molecule splicing modulator compounds that modulate splicing of mRNA, pharmaceutical compositions comprising those compounds, and methods of use for treating disease and conditions. The patent was allowed with 14 claims under CPC classifications C07D 451/06 and C07D 451/14. This represents a standard patent grant for a novel therapeutic compound family in the RNA splicing modulation space.
For pharmaceutical and biotechnology companies developing RNA-targeted therapeutics, this patent establishes intellectual property protection for a specific chemical scaffold (Formula II compounds) and their use in modulating splicing. Competitors in the RNA splicing modulation field should conduct freedom-to-operate analyses to assess potential overlap with the claimed compounds and methods.
Archived snapshot
Apr 28, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
Methods and compositions for modulating splicing
Grant US12612397B2 Kind: B2 Apr 28, 2026
Assignee
Skyhawk Therapeutics, Inc.
Inventors
Michael Luzzio, Brian Lucas, Daniel Brian Horne
Abstract
Described herein are small molecule splicing modulator compounds that modulate splicing of mRNA, such as pre-mRNA, encoded by genes, pharmaceutical compositions comprising the same, and methods of the small molecule splicing modulator compounds for modulating splicing and treating disease and conditions. In one aspect, disclosed herein are small molecule splicing modulators having a structure of Formula (II), or pharmaceutically acceptable salts thereof.
CPC Classifications
C07D 451/06 C07D 451/14
Filing Date
2021-07-29
Application No.
17388097
Claims
14
Mentioned entities
Parties
Related changes
Get daily alerts for USPTO Patent Grants - Organic Chemistry (C07D)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from USPTO.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when USPTO Patent Grants - Organic Chemistry (C07D) publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.